NCT01618955View on ClinicalTrials.gov

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Rheumatoid Arthritis (RA)
Interventions
DEVICE

VIBEX MTX

Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device

Trial Locations (1)

16635

Altoona Center for Clinical Research, Duncansville

Sponsors
All Listed Sponsors
lead

Antares Pharma Inc.

INDUSTRY

NCT01618955 - Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device | Biotech Hunter | Biotech Hunter